Table 3.

Generalized logistical mixed-effect model of the relationship between SSRIs and PSF during the 24-month follow-up period.

	Model 1		Model 2
	OR (95% CI)	P value	OR (95% CI)	P value
All patients (n = 847)
Treatment	0.837 (0.694–1.011)	0.064	0.991 (0.976–1.007)	0.343
Time	0.688 (0.615–0.769)	<0.001	0.970 (0.961–0.980)	<0.001
PSD group (n = 249)
Treatment	0.952 (0.928–0.976)	<0.001	0.955 (0.928–0.984)	0.002
Time	1.001 (0.981–1.022)	0.903	0.997 (0.973–1.022)	0.823
Non-PSD group (n = 598)
Treatment	1.029 (0.790–1.338)	0.834	1.008 (0.984–1.033)	0.520
Time	0.658 (0.587–0.738)	<0.001	0.965 (0.954–0.975)	<0.001

Model 1: Unadjusted; Model 2: The model was adjusted for age, sex, body mass index, hypertension, diabetes mellitus, hyperlipemia, smoking, drinking, TOAST classification., NIHSS, HAMA and Lubben score.

CI, confidence interval; HAMA, Hamilton Anxiety Scale; NIHSS, NIH Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; OR, odds ration; PSD, poststroke depression; PSF, poststroke fatigue.